Adenosine 3;5'-cyclic monophosphate (cAMP) or guanosine 3;5'-cyclic monophosphate (cGMP) has been reported to play an important role in smooth muscle relaxation (1, 2). How smooth muscle contractility is affected by phosphodiesterase (PDE) inhibitors, which increase intracelluar cAMP and/or cGMP, has been in vestigated (3, 4) . Recently, PDE isozymes have been clas sified into types I to VII (5). Selective inhibitors have been developed for some of the subtypes (6): nicardipine (Ca 2+ antagonist), W-7 and trifluoperazine (calmodulin inhibitor) and vinpocetine are specific for type I; milri none, amrinone, vesnarinone, etc., for type III; rolipram and Ro20-1724 for type IV; zaprinast and dipyridamole for type V. These selective PDE isozyme inhibitors have been utilized as a vasodilator, antihypertensive drug and bronchodilator, and they have been employed to eluci date the mechanism of relaxation in smooth muscle. The effect of these inhibitors on the smooth muscle has been studied mainly in blood vessels and tracheae. The selec tive PDE III inhibitor milrinone markedly inhibited the serotonin-induced contraction in rat aorta (7) and the phenylephrine-induced contraction in guinea pig aorta (8). Other selective PDE III inhibitors also significantly inhibited serotonin-induced contractions (7) and norepi nephrine-induced contractions (9-11) in rat aorta. On the other hand, selective PDE IV inhibitors caused relaxation in guinea pig trachea, and the combination of a PDE IV inhibitor with a PDE III inhibitor produced further relaxation (12). However, except for the study by Small et al. (13) , there have been no other studies on the effects of selective PDE inhibitors on intestinal smooth muscle. Therefore, we investigated the mechanism of the inhibi tory effect of the non-selective inhibitor 3-isobutyl-l methyl xanthine (IBMX) and those of the selective inhi bitors milrinone, Ro20-1724 and zaprinast on muscle contractility of guinea pig ileal longitudinal smooth muscle by measuring muscle tension, intracellular Ca 21 ([Ca 21],) level, cAMP and cGMP contents in intact mus cle strips and Ca2+-induced contractions in a muscle per meabilized by a-toxin or Triton X-100.
MATERIALS AND METHODS

Muscle preparations and tension measurement
Male guinea pigs (Hartley strain 300-400 g; Funabashi Farm, Funabashi) were bled after stunning, and then the ileum of each animal was quickly removed. The lon gitudinal smooth muscle layer was stripped from the cir cular one as described by Paton and Aboo Zar (14) . The muscle strips were about 5 8 mm in width and 15 mm in length. One end of each strip was bound to a glass holder and the other end was connected to a strain-gauge trans ducer (TB-611T; Nihon Kohden, Tokyo) with silk thread. The samples were equilibrated in a physiological salt so lution (PSS) in an organ bath. The muscle tension was isometrically recorded.
Assay of cAMP and cGMP contents in the ileal lon gitudinal muscle cAMP or cGMP content in the ileal longitudinal muscle was measured by enzyme immunoassay. After an incubation of the muscles with IBMX, milrinone, Ro20-1724 or zaprinast for 10 min in the presence of 1 pM carbachol (CCh), muscles were rapidly frozen in liquid nitrogen and stored at 801C until homogenized in 6% trichloroacetic acid (0.4 ml). The homogenate was cen trifuged at 3000 x g for 15 min, and the supernatant obtained was washed with water-saturated diethylether three times. cAMP or cGMP content was assayed by an enzyme immunoassay kit (Cayman Chemical Company, Ann Arbor, MI, USA). cAMP and cGMP contents are expressed as pmol/g wet wt.
Simultaneous measurement of muscle tension and [Ca2+1; level The [Ca 2+]; level was measured simultaneously with muscle tension as described previously (15). Muscle strips were incubated with 5 pM fura2/AM for 3-4 hr at room temperature. Then 0.02% cremophor EL, a noncytoxic detergent, was added to increase the solubility of fura2/AM. One end of the muscle was pinned to the bot tom of an organ bath filled with 8 ml of PSS, and the other end was attached to the transducer with silk thread. The muscle strip was kept horizontally in the organ bath. The muscle strip was alternately excited with light at 340 nm and 380 nm through the rotating filter wheel, and then the 500 nm emission was measured with a fluorimeter (CAF-100; Japan Spectroscopic Co., Ltd., Tokyo).
Measurement
of muscle tension in a permeabilized smooth muscle A thin longitudinal muscle strip, 5.0 mm in length and 0.2 mm in width, was prepared from the isolated ileum as described above. The muscle strip was held horizontally in an 1-ml organ bath. One end of each strip was fixed and the other end was connected to a strain-gauge trans ducer. The muscle tension was isometrically recorded.
a-Toxin treated muscle: A permeabilized muscle was made by treating the isolated muscle with a relaxing solution (RS-I) containing 40 pg/ml a-toxin for 20 min at room temperature as described by Nishimura and van Breemen (16) and Kitazawa et al. (17) . Triton X-100 treated muscle: The muscle was perme abilized as described by Sparrow et al. (18) , with the fol lowing modification: The muscle strips were first incu bated in solution A (pH 7.4) (see, Solutions) for 60 min at 41C ; then 1 % Triton X-100 and 0.5 mM dithioerythritol (DTE) were added to this solution and incubation was carried out for 4 hr more at 4C. °After rinsing for 15 min in solution A containing 0.5 mM DTE, the strips were stored in solution B (pH 6.7) (see, Solutions) at -20°C for up to 5 days. The RS-II was entirely exchanged for each drug trial.
Solutions PSS employed was a modified Tyrode's solution (136.8 mM NaC1, 5.4 mM KCI, 1.5 mM CaCl2i 1.0 MM MgC12, 11.9 mM NaHCO3 and 5.5 mM glucose), which was aerated with a 95% 02 and 5% CO2 at 371C (pH 7.2). Hyperosmotically added 65.4 mM KCl (H-65K+) solution was made by increasing the concentration of KCl in the PSS.
In the experiment of the [Ca 211, measurement, isos motically added 77 mM KCI (I-77K+) solution was made by substituting an equimolar amount of K+ for Na+ in the PSS, because Himpens and Somlyo (19) suggested that a change of osmotic pressure induced a change of fura2-fluorescence.
In the experiment with the a-toxin permeabilized muscle, RS-I contained 130 mM potassium propionate, 4 mM MgC12i 4 mM ATP, 20 mM tris-maleate, 2 mM creatine phosphate, 10 U/ml creatine phosphokinase and 2 mM ethyleneglycol bis-(~-aminoethylether)-N, N, N; N' tetraacetic acid (EGTA). The solution was adjusted to pH 6.8 at 24C with KOH (0.1 N). In the experiment with the Triton X-100 permeabilized muscle, solution A contained 20 mM imidazole, 5 mM EGTA, 50 mM KCI and 150 mM sucrose. Solution B contained 20 mM imidazole, 2 mM EGTA, 10 MM MgC12, 1 mM NaN3, 0.5 mM DTE with 50% glycerol. RS-II contained 50 mM KCI, 20 mM im idazole, 8 MM MgC12, 4 mM ATP, 3 mM KH2PO4, 3 mM K2HPO4, 0.1 pM calmodulin and 1 mM NaN3, adjusted to pH 6.7.
Chemicals
Chemicals used were IBMX, milrinone, zaprinast, CCh, verapamil, EGTA, cGMP, 8-bromoguanosine 3;5'-cyclic monophosphate (8-Br-cGMP, a membrane-permeant cGMP analogue), forskolin (Sigma Chemical Co., St. Louis, MO, USA); Ro20-1724 (4-(3-butoxy-4-methoxyphenyl) methyl-2-imidazolidone) ( (Fig. 1) . The inhibitions by these agents took as long as 10 min after their addition to reach steady state levels. Table 1 summarizes the concentrations of the PDE inhibitors producing 50% relaxation (IC50) of H-65K+ or CCh-induced contraction. The results also showed that the inhibitory effects of milrinone and Ro20-1724 on the contractile response were remarkably smaller than those of IBMX and zaprinast.
Effects of PDE inhibitors on cGMP and cAMP contents As shown in Fig. 2 , both IBMX (3, 30 and 300 pM) and zaprinast (1, 10 and 100 pM) concentration-dependently increased the cGMP contents of the muscle strips in the presence of 1 pM CCh. The increase of cGMP content by 300 pM IBMX and 100 pM zaprinast reached 13.5 and 12.8 times above the control level, respectively. Milrinone (100 pM) and Ro20-1724 (100 pM) did not significantly change the cGMP content (data not shown). Figure 3 illustrates the cGMP-relaxation relation obtained by the addition of IBMX, zaprinast or nitroprusside (1,10 and 100 pM) in the presence of 1 pM CCh. It shows that despite a high correlation between inhibition of the muscle tension and the increase of cGMP content in the presence of IBMX, zaprinast or nitroprusside, the cGMP-relaxation relation of IBMX or zaprinast is located to the left of that obtained in the presence of nitroprusside. This indicates that a larger relaxation was induced in the presence of IBMX or zaprinast than in the presence of nitroprusside for a given increase in cGMP content. 
zaprinast (/) or nitroprusside (A) on relaxation (ordinate) and the cGMP
In the presence of 1 pM CCh, both milrinone (1, 10 and 100 I M) and Ro20-1724 (1, 10 and 100 pM) increased the cAMP content of the muscle strips in a concentration-de pendent manner (Fig. 4) . Furthermore, IBMX (300 pM) or zaprinast (100 pM) also significantly increased the cAMP content of the muscle strips above the control, to levels that were similar to those induced by milrinone (100 pM) or Ro20-1724 (100 pM) (Fig. 5) . Figure 6 illustrates the cAMP-relaxation relation obtained by the addition of milrinone, Ro20-1724 or forskolin (1, 10 and 100 ppM) in the presence of 1 pM CCh. It shows that despite the high correlation between inhibition of the muscle tension and the increase of cAMP content in the presence of Ro20 1724 or forskolin, the cAMP-relaxation relation of Ro20 1724 is located to the left of that obtained in the presence of forskolin. This indicates that a larger relaxation was induced in the presence of Ro20-1724 than in the presence of forskolin for a given increase in cAMP content. 
Effects of IBMX, zaprinast, nitroprusside and 8-Br cGMP on [Ca2 +]t level
The effects of IBMX, zaprinast, nitroprusside and 8 Br-cGMP on [Ca 2+], level were measured simultaneously with muscle tension by using a fluorescent Ca2+ indicator, fura2. I-77K+ or 1 pM CCh increased the muscle tension and the elevated [Ca 2+1, level was indicated by a change in F340/F380. IBMX (300 pM) inhibited the 1-77K+-in duced contraction and [Ca 2+], level (Fig. 7, Table 2 ). The sequential addition of 10 pM verapamil further decreased both the muscle tension and [Ca 2+], level to the resting levels (Fig. 7) . The inhibitory effects of IBMX on the CCh-induced contraction and elevated [Ca 2+]; level were similar to those on the 1-77K+-induced contraction (Fig.  7, Table 2 ). Zaprinast (100 pM) inhibited both the I 77K+ and 1 pM CCh-induced contractions and [Ca 2+], level (Fig. 8, Table 2 ). In summary, IBMX and zaprinast markedly inhibited the muscle tension but only slightly inhibited the [Ca 2+]; level. Nitroprusside (100 pM) and 8 Br-cGMP (1 mM) also inhibited both the 1-77K+ and CCh-induced contractions remarkably, but only slightly inhibited the [Ca 2+1, level. The inhibition of the [Ca 2+]; level by nitroprusside was smaller than that by IBMX (Table 2) .
Effects of cGMP on Ca2+-induced contractions in per meabilized muscle
As shown in Fig. 9 , 1 sM Ca 2+ induced a sustained contraction in the a-toxin-permeabilized muscle. cGMP (100 pM) inhibited the 1 PM Ca2+-induced contraction to 24.6 ± 3.3 %. IBMX (300 pM) or zaprinast (100 pM) also inhibited the contraction to 49.9±3.4% or 47.2±7.9%, respectively. In the Triton X-100-permeabilized muscle, 3 pM Ca 2+ also induced a sustained contraction. IBMX (300 pM) or zaprinast (100 pM), however, rather enhanced the con tractions to 11.6--E2.611/0 or 16.7--L0.7%, respectively. 
DISCUSSION
The present study on the contractility of guinea pig ileal longitudinal muscle revealed that inhibitory effects of a non-selective PDE inhibitor, IBMX, and a selective PDE V inhibitor, zaprinast, were remarkable on high K+ or CCh-induced contraction, while those of a selective PDE III inhibitor, milrinone, and a selective PDE IV inhibitor, Ro20-1724, were small (Fig. 1, Table 1 ). It is well-known that selective PDE III or IV inhibitors induce a remark able relaxation in vascular or tracheal smooth muscles. Therefore, these results suggest that the effect of selective PDE inhibitors on intestinal smooth muscles are different from that on vascular or tracheal smooth muscle. IBMX and zaprinast increased the cGMP content of ileal longitudinal muscle in a concentration-dependent manner, although Ro20-1724 and milrinone had no effect on them. It is thought that increases in cGMP content by IBMX and zaprinast were caused by inhibition of PDE V. On the other hand, zaprinast also elevated the cAMP content of the muscle strips above the control level. There are two possibilities to explain this result: 1) Zaprinast slightly inhibits PDE isozymes (I, II, III, IV) that hydro lyze cAMP. 2) cGMP that was increased through an inhibition of PDE V by zaprinast inhibits PDE III that hydrolyzes cAMP (20). The resting tension and [Ca 2+]i level (F340/F380) were taken as 100% inhibition, and the tension and [Ca 2+]; level after adding the stimulants to the bath were taken as 0'o inhibition. In the present experiment, there was a high correlation between inhibition of the muscle tension and the increase of cGMP under the treatment with IBMX, zaprinast or sodium nitroprusside in the presence of CCh. Moreover, 8-Br-cGMP inhibited the high K+ or CCh-induced con traction in the ileal longitudinal muscle (Table 2) . These results suggest that the relaxation induced by IBMX or zaprinast is involved in the increases of cGMP content. However, in comparison to the relaxation by nitroprus side, IBMX or zaprinast appears to induce a larger relax ation at a given cGMP content. It is assumed that the smaller relaxation by nitroprusside at a given cGMP con tent is involved in an overactivation of guanylate cyclase; if not, the greater relaxation by IBMX or zaprinast is influenced by another factor such as induction of cGMP sensitization in the intestinal smooth muscle.
It is known that isoproterenol that enhances cAMP contents of the muscle strip inhibits muscle tension in in testinal smooth muscles (21). In the present study, both milrinone and Ro20-1724 also concentration-dependently increased the cAMP content of the Real longitudinal muscle. However, these agents had no effect on the cGMP content. There was a high correlation between the inhibi tion of muscle tension and the increases of cAMP under the treatment with Ro20-1724 or forskolin in the presence of CCh. However, compared to the relaxation by fors kolin, Ro20-1724 appears to induce a larger relaxation at a given cAMP content. We think this difference can be ex plained by the same assumption for the difference among IBMX, zaprinast and nitroprusside with regards to the correlation between the cGMP content and relaxation. These results suggest that IBMX and zaprinast inhibit muscle tension mainly through the increase in cGMP, and Ro20-1724 inhibited it mainly through the increase in cAMP. Although milrinone increased the cAMP content, it induced only a small relaxation.
The data probably exclude the possibility that milrinone is involved in the cAMP sensitization in the smooth muscle.
In the present study, we investigated the relaxing mechanism of IBMX and zaprinast that show potent in hibition of muscle tension and the increase in cGMP con tent in ileal longitudinal muscle. It has been reported that sodium nitroprusside (22, 23), 8-Br-cGMP (22) and endothelium-derived relaxing factor (EDRF) (22) influx, the increase in Ca2+ efflux and/or the increase in Ca2+ sequestration in the ileal longitudinal muscle. However, the decrease of [Ca 211, level by cGMP seems to contribute partially to the inhibition of muscle tension because the decrease in [Ca 2+], level was smaller than that in muscle tension. In the present experiment, cGMP, IBMX and zaprinast significantly inhibited the Ca 2+-in duced contraction in the a-toxin permeabilized ileal lon gitudinal muscle. Similarly, cGMP was reported to in hibit the Ca2+-induced contraction in a concentration-de pendent manner in rat mesenteric artery permeabilized by a-toxin but retaining signal transduction systems (16). These results suggest that the inhibition of contraction by IBMX or zaprinast is partially related to the decrease in the sensitivity of contractile protein to Ca2+. On the other hand, the possibility that the inhibition of Ca 21 -induced contraction by IBMX or zaprinast is directly related to an inhibition of contractile protein was excluded by the result that IBMX or zaprinast rather enhanced the Ca2+ induced contraction in the Triton X-100 permeabilized muscle that lost its signal transduction system and abil ity of Ca2+ sequestration in sarcoplasmic reticulum.
It is generally thought that a receptor agonist binds to a receptor and its stimulation generates inostiol-1,4,5, trisphosphate and diacylglycerol by phosphatidyl-inositol turnover. In smooth muscles, these products are involved in contraction. Rapoport (24) reported that cGMP in hibited norephinephrine-induced contraction by inhibit ing phosphatidyl-inositol turnover in the aorta. In the present experiment, zaprinast inhibited the high K+ or CCh-induced contraction in ileal longitudinal muscle with a similar level of IC50, suggesting that phosphatidyl inositol turnover is not involved in the relaxation of ileal longitudinal muscle in the presence of high K+ or CCh.
In summary, IBMX and zaprinast inhibit the muscle tension in guinea pig ileal longitudinal smooth muscle mainly through an increase in cGMP, while Ro20-1724 inhibits contraction mainly through an increase in cAMP. The inhibitory mechanism of IBMX or zaprinast is in volved in the decrease in [Ca 211, level and the decrease in the sensitivity of contractile elements to Ca2+.
